- ICH GCP
- Реестр клинических исследований США
- Клиническое испытание NCT02885857
Safety and Efficacy of Shenyankangfu Tablets for Chronic Kidney Disease
Обзор исследования
Статус
Условия
Вмешательство/лечение
Подробное описание
Research purpose: Safety and efficacy of long-term application of Shenyankangfu Tablets in Large sample of patients with chronic kidney disease.
The crowd: patients with primary glomerular nephritis, diabetic nephropathy patients.
Study design: a multicenter clinical study design, openness. The study drug: Shenyan Kangfu Tablets. Statistical analysis: Research plan is determined, by statistical professionals responsible for negotiation with the principal investigator for statistical analysis plan.
Тип исследования
Регистрация (Ожидаемый)
Фаза
- Фаза 4
Контакты и местонахождение
Места учебы
-
-
Beijing
-
Beijing, Beijing, Китай
- Рекрутинг
- Guang'anmen Hospital, China Academy of Chinese Medical Sciences
-
Beijing, Beijing, Китай, 100853
- Рекрутинг
- National Clinical Research Center for Kidney Disease, State Key Laboratory of Kidney Disease, Department of Nephrology, Chinese PLA General Hospital
-
Контакт:
- jie wu, doctor
- Электронная почта: wujie301@163.com
-
Главный следователь:
- xiangmei chen, doctor
-
-
Chongqing
-
Chongqing, Chongqing, Китай
- Рекрутинг
- Daping Hospital,Research Institute of Surgery Third Military Medical University
-
-
Fujian
-
Fuzhou, Fujian, Китай
- Рекрутинг
- Fuzhou General Hospital Nanjing Military Command
-
Xiamen, Fujian, Китай
- Рекрутинг
- 174th hospital of the People's Liberation Army
-
-
Hebei
-
Qinhuangdao, Hebei, Китай
- Рекрутинг
- Beidaihe Sanatorium of Beijing Military Mrca
-
-
Heilongjiang
-
Harbin, Heilongjiang, Китай
- Рекрутинг
- Heilongjiang University of Chinese Medicine
-
-
Henan
-
Zhengzhou, Henan, Китай
- Рекрутинг
- Henan Provincial People's Hospital
-
-
Shandong
-
Jinan, Shandong, Китай
- Рекрутинг
- Shandong Province Hospital
-
-
Shanghai
-
Shanghai, Shanghai, Китай
- Рекрутинг
- Changhai Hospital of Shanghai
-
Shanghai, Shanghai, Китай
- Рекрутинг
- LONGHUA Hospital Shanghai University of TCM
-
-
Shanxi
-
Taiyuan, Shanxi, Китай
- Рекрутинг
- First Hospital of Shanxi Medical University
-
-
Tianjin
-
Tianjin, Tianjin, Китай
- Рекрутинг
- First Teaching Hospital of Tianjin University of TCM
-
-
Критерии участия
Критерии приемлемости
Возраст, подходящий для обучения
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Описание
Inclusion Criteria:
- Diagnosed with primary glomerulonephritis or diabetic nephropathy;
- Aged from 18 to 70 years,male or female
- GFR≥45ml/min/1.73㎡
- 0.5g≤24 hours proteinuria≤3.0g
- glycated hemoglobin (HbAlc) ≤8% (This has been limited to patients with diabetic nephropathy)
- Traditional Chinese medicine syndrome conform Qi-Yin Deficiency
- Obtain the agreement of patients or their guardians, and signed informed consent file
Exclusion Criteria:
- Secondary nephropathy
- People allergic to Shenyankangfu tables
- Combined with severe primary disease of heart, brain, liver and hematopoietic system, or other serious diseases can affect patient's life
- Pregnant or lactating women
- Be participating in another clinical study at the same period
Учебный план
Как устроено исследование?
Детали дизайна
- Основная цель: Уход
- Распределение: Н/Д
- Интервенционная модель: Одногрупповое задание
- Маскировка: Нет (открытая этикетка)
Оружие и интервенции
Группа участников / Армия |
Вмешательство/лечение |
---|---|
Экспериментальный: Shenyan kangfu Tablets
Shenyan Kangfu Tablets;Each weighing 0.48g;Oral;Once five, three times a day
|
Observation period: 24 weeks.
The dosage regimen: each piece weighs 0.48 g. 5 / time, 3 times daily, orally after dinner.
|
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Временное ограничение |
---|---|
24-hour urinary protein excretion
Временное ограничение: Observation time: 24 weeks.Tested once every 12 weeks, it was detected three times
|
Observation time: 24 weeks.Tested once every 12 weeks, it was detected three times
|
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
---|---|---|
Serum creatinine
Временное ограничение: Observation time: 24 weeks.Tested once every 12 weeks, it was detected three times
|
Observation time: 24 weeks.Tested once every 12 weeks, it was detected three times
|
|
Glomerular filtration rate
Временное ограничение: Observation time: 24 weeks.Tested once every 12 weeks, it was detected three times
|
Observation time: 24 weeks.Tested once every 12 weeks, it was detected three times
|
|
Albumin
Временное ограничение: Observation time: 24 weeks.Tested once every 12 weeks, it was detected three times
|
Observation time: 24 weeks.Tested once every 12 weeks, it was detected three times
|
|
Glycated hemoglobin
Временное ограничение: Observation time: 24 weeks.Tested once every 24 weeks, were detected in 2 times
|
Observations of the project value and the percentage change in value before and after the treatment.
|
Observation time: 24 weeks.Tested once every 24 weeks, were detected in 2 times
|
Symptom scores
Временное ограничение: Observation time: 24 weeks.Tested once every 12 weeks, it was detected three times
|
Observation time: 24 weeks.Tested once every 12 weeks, it was detected three times
|
Другие показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
---|---|---|
Routine blood test
Временное ограничение: Observation time: 24 weeks.Tested once every 12 weeks, it was detected three times
|
Observation time: 24 weeks.Tested once every 12 weeks, it was detected three times
|
|
Routine urine test
Временное ограничение: Observation time: 24 weeks.Tested once every 12 weeks, it was detected three times
|
Observation time: 24 weeks.Tested once every 12 weeks, it was detected three times
|
|
Liver function
Временное ограничение: Observation time: 24 weeks.Tested once every 12 weeks, it was detected three times
|
Observation time: 24 weeks.Tested once every 12 weeks, it was detected three times
|
|
Renal function tests
Временное ограничение: Observation time: 24 weeks.Tested once every 12 weeks, it was detected three times
|
Observation time: 24 weeks.Tested once every 12 weeks, it was detected three times
|
|
Potassium detection
Временное ограничение: Observation time: 24 weeks.Tested once every 12 weeks, it was detected three times
|
Observation time: 24 weeks.Tested once every 12 weeks, it was detected three times
|
|
blood glucose testing
Временное ограничение: Observation time: 24 weeks.Tested once every 12 weeks, it was detected three times
|
Observation time: 24 weeks.Tested once every 12 weeks, it was detected three times
|
|
Electrocardiograph
Временное ограничение: Observation time: 24 weeks.Tested once every 24 weeks, were detected in 2 times
|
Observation time: 24 weeks.Tested once every 24 weeks, were detected in 2 times
|
|
chest radiography
Временное ограничение: Observation time: 24 weeks.Tested once every 24 weeks, were detected in 2 times
|
Observation time: 24 weeks.Tested once every 24 weeks, were detected in 2 times
|
|
Adverse events / adverse reactions
Временное ограничение: Observation time: 24 weeks.Tested once every 24 weeks, were detected in 2 times
|
Follow-up 3 times.Subject at any time to contact your doctor.
|
Observation time: 24 weeks.Tested once every 24 weeks, were detected in 2 times
|
Соавторы и исследователи
Спонсор
Соавторы
Следователи
- Главный следователь: YongLi Zhan, investigator, Guang'anmen Hospital of China Academy of Chinese Medical Sciences
- Главный следователь: HongTao Yang, investigator, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine
- Главный следователь: Meng Liang, investigator, 174th hospital of the People's Liberation Army
- Главный следователь: Lu Ma, investigator, Beidaihe Sanatorium of Beijing Military Mrca
- Главный следователь: LiQun Song, investigator, Heilongjiang University of Chinese Medicine
- Главный следователь: QiaoLing Zhou, investigator, Xiangya Hospital of Central South University
- Главный следователь: Ping Luo, investigator, Second Hospital of Jilin University
- Главный следователь: RongShan Li, investigator, Shanxi provincial peple's hospital
- Главный следователь: XiaoHong Cheng, investigator, Shaanxi Traditional Chinese Medicine Hospital
- Главный следователь: Jie Wu, investigator, Chinese PLA General Hospital
Даты записи исследования
Изучение основных дат
Начало исследования
Первичное завершение (Ожидаемый)
Завершение исследования (Ожидаемый)
Даты регистрации исследования
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Оценивать)
Обновления учебных записей
Последнее опубликованное обновление (Оценивать)
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Дополнительные соответствующие термины MeSH
Другие идентификационные номера исследования
- S2015-023-02
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .
Клинические исследования Shenyan Kangfu Tablet
-
Hevert-Arzneimittel GmbH & Co. KGЗавершенный
-
China Academy of Chinese Medical SciencesPeking University First Hospital; Peking Union Medical College Hospital; Chengdu University... и другие соавторыНеизвестный
-
Kremers Urban Development CompanyЗавершенный
-
University Hospital, Clermont-FerrandDr Gisèle PICKERING (MCU-PH)(Clinical Pharmacology center, Inserm 501); Dr Gilles...Завершенный
-
Daewoong Pharmaceutical Co. LTD.РекрутингИдиопатический легочный фиброзСоединенные Штаты, Корея, Республика
-
University of Maryland, BaltimoreNational Center for Advancing Translational Sciences (NCATS); University of Maryland...ЗавершенныйТравма | Травматическое повреждение мозга | Боль, острый | Посттравматические головные болиСоединенные Штаты
-
Kremers Urban Development CompanyЗавершенныйЗдоровыйСоединенные Штаты
-
Pharma PlantNovagenix Bioanalytical Drug R&D CenterНеизвестный
-
Chong Kun Dang PharmaceuticalЗавершенныйРевматоидный артритКорея, Республика
-
Hunan Kelun Pharmaceutical Co., Ltd.Завершенный